The molecular pathogenesis of primary mediastinal large B-cell lymphoma.
about
Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overviewThe genetic landscape of diffuse large B-cell lymphomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewPrognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma.Composite Lymphoma: Opposite Ends of Spectrum Meet.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Comparison of pediatric and adult lymphomas involving the mediastinum characterized by distinctive clinicopathological and radiological features.FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma.Primary mediastinal large B-cell lymphoma.A minimal connected network of transcription factors regulated in human tumors and its application to the quest for universal cancer biomarkersPrimary mediastinal lymphoma: diagnosis and treatment options.Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphomaMutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples.Grey zone lymphomas: lymphomas with intermediate features.Genetic lesions in diffuse large B-cell lymphomasGene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphomaNon-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions.Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapyTargetable genetic features of primary testicular and primary central nervous system lymphomas.STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL).Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.The B7 homologues and their receptors in hematologic malignancies.Signaling pathways in lymphoma: pathogenesis and therapeutic targets.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Structural genomic alterations in primary mediastinal large B-cell lymphoma.IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate types.The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.Knock-down of BCL6 / STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agents.Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Lentiviral vector-mediated siRNA knockdown of c-MYC: cell growth inhibition and cell cycle arrest at G2/M phase in Jijoye cells.Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.
P2860
Q26769596-BCD72B06-D667-44E5-B742-28216F403DC2Q26866537-CB6536A1-7D7A-4FC1-8C2C-158DDBF7B235Q27304386-6D97B80F-2345-4614-BF3E-62E61BB95489Q31116522-FAB150BB-3D03-4E88-AC52-E4B8C85871D6Q33168244-135F920F-274E-4E81-8196-99603F3CC113Q33622342-94A11822-99FB-4BBF-BD15-33AD4D409C07Q33747063-F7C5C576-6D1B-4C5B-BDE2-D6238BA311B2Q34221760-630EAB09-3724-4A7D-97F3-6F93C276B5CDQ34266819-B72F435D-117B-42F2-8EFC-AFF3FDFF2E88Q34326409-931F5C09-FFFF-46F0-ADFD-57FBB988A49CQ34455499-8DC6C99E-63EF-4122-B868-88C86DA9BCCBQ34612336-D4D7217A-E239-4658-9A61-CF968615E8E1Q34636963-3F5FC8C0-2214-4A01-9A1B-176846DF7CEDQ35882774-60062A81-FD6B-4E0F-8E1B-671F8686CCC7Q35974341-698641B1-95C7-453E-AB3D-8E7993161E90Q36051184-C19808D1-2DB6-4DFB-9726-C809A867D708Q36474669-EAA5E918-BB00-4F6B-9D18-C34E486E43ABQ36529482-59F1F0C6-ECC6-4281-A1AC-0E0C1BC650B2Q36596879-80D83323-2FFA-4A7F-8932-B2415A3426A5Q37138531-00389741-8AFE-4AE2-AB80-A963412EF5AEQ37725413-423CE069-D927-4761-8BE6-B141C0657BBEQ37988965-D2E81A85-59CA-40E2-96EA-D75C8BB445A4Q38150876-1EB10F94-EB5C-4043-984D-A2A2DEC52540Q38161760-2A11EA5B-31BF-4277-AE26-C4C2B4990E71Q38203924-6B42E168-6CBF-41DC-9C7D-5C7E9DDEE443Q38240579-3D122E4D-5A1B-41F3-B84C-0E0F116D0E4EQ38267888-49B461D4-016C-4EAE-B30B-77EE1903D6B3Q38523971-E7CC3B41-AD0C-4B19-8CB4-45B593F428CAQ38664822-88011A77-4BCC-4F01-9C3E-0B4EC96E1823Q38754419-29542B08-D538-4C78-AFBC-2B136933D017Q38764010-C6E0A106-5D4F-4854-8AF4-745C972D8876Q38782141-4A5273AA-2322-4851-BD01-F767AFBBF1BFQ38822525-DC065923-9164-4518-8F53-3FB1502EB92CQ38882112-F674F01E-3701-417B-8A64-98D1666056AAQ38902828-0281B364-E797-45D9-A294-21DA6ECD530BQ38919386-0C47D597-155E-4983-A6E5-9CA4A646AF4AQ38933091-60290DF3-ED52-4B53-9BD2-A8E324029D06Q38996724-17ED5391-2912-4935-A20B-DB1439DBA450Q39154624-FF3BF8F0-F1EB-432B-B941-23BCA0197685Q42368339-1B08C382-1F93-4540-ADD8-4E846CDDC15C
P2860
The molecular pathogenesis of primary mediastinal large B-cell lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The molecular pathogenesis of primary mediastinal large B-cell lymphoma.
@en
The molecular pathogenesis of primary mediastinal large B-cell lymphoma.
@nl
type
label
The molecular pathogenesis of primary mediastinal large B-cell lymphoma.
@en
The molecular pathogenesis of primary mediastinal large B-cell lymphoma.
@nl
prefLabel
The molecular pathogenesis of primary mediastinal large B-cell lymphoma.
@en
The molecular pathogenesis of primary mediastinal large B-cell lymphoma.
@nl
P1433
P1476
The molecular pathogenesis of primary mediastinal large B-cell lymphoma.
@en
P2093
Christian Steidl
P304
P356
10.1182/BLOOD-2011-05-326538
P407
P577
2011-06-23T00:00:00Z